BridgeBio is significantly improved the course of a novel therapy for ATTR-CM, utilizing the investigational drug. Initial patient information reveals significant benefits for those affected from the debilitating https://bridgebio066222.bluxeblog.com/74603644/company-progresses-cardiac-amyloidosis-therapy-with-the-drug